Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 4/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30412907 | 1.00 | PNMT (0.60) | PNMTTAAR1DPP4IDO1GABRA1 | |
| SCHEMBL625763 | 0.82 | PNMT (0.75) | PNMTTAAR1DPP4IDO1LOXL2 | |
| SCHEMBL845149 | 0.81 | TSHR (0.39) | PNMTTAAR1IDO1GABRA1GABRB2 | |
| SCHEMBL20818578 | 0.81 | TSHR (0.39) | PNMTTAAR1IDO1GABRA1GABRB2 | |
| SCHEMBL29900365 | 0.81 | TSHR (0.39) | PNMTTAAR1IDO1GABRA1GABRB2 | |
| SCHEMBL29925179 | 0.81 | TSHR (0.39) | PNMTTAAR1IDO1GABRA1GABRB2 | |
| SCHEMBL31152963 | 0.79 | GABRA1 (0.56) | PNMTTAAR1IDO1GABRA1GABRB2 | |
| SCHEMBL1746640 | 0.79 | PNMT (0.37) | PNMTTAAR1IDO1GABRA1GABRB2 | |
| SCHEMBL29900362 | 0.79 | PNMT (0.37) | PNMTTAAR1IDO1GABRA1GABRB2 | |
| SCHEMBL28958233 | 0.78 | TAAR1 (0.48) | PNMTTAAR1DPP4IDO1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618985-A1 | DUAL INHIBITORS OF SIGMA-1 RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE AND THEIR USE IN THE TREATMENT OF PAIN | Universitat De Barcelona (ES) | 2025-09-24 | — | — | EP | disclosed |
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT PASTEUR DE LILLE (FR) | 2024-10-03 | — | — | US | disclosed |
| WO-2024163166-A1 | BORON CONTAINING COMPOUNDS AND THEIR USES | 5METIS, INC. (US) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024105234-A1 | DUAL INHIBITORS OF SIGMA-1 RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE AND THEIR USE IN THE TREATMENT OF PAIN | UNIVERSITAT DE BARCELONA (ES) | 2024-05-23 | — | — | WO | disclosed |
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023066357-A1 | FUSED CYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-04-27 | — | — | WO | disclosed |
| WO-2023046198-A1 | SULFA KETONE COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2023-03-30 | — | — | WO | disclosed |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2023002011-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-01-26 | — | — | WO | disclosed |
| EP-3022182-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
| US-8557853-B2 | Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents | ALLERGAN, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20080318929-A1 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| EP-1966163-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | Boehringer Ingelheim International GmbH (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2007076247-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-05 | — | — | WO | disclosed |
| CN-1016175-B | Imidazoquinoline antithrombin cardiotonic agents | BRISTOL MYERS CO (US) | 1992-04-08 | — | — | CN | disclosed |
| CN-86102747-A | The preparation method of imidazoquinoline antithombogehic cardiotonic agents | — | 1987-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ATP4B | PNMT 875/4885TAAR1 4822/4885DPP4 258/4885 |
| US-20080318929-A1 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta | PRKCQ, PRKCZ, PRKAR2B | PNMT 1075/4885TAAR1 2892/4885DPP4 1647/4885 |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | HIPK1, HIPK2, IP6K1 | PNMT 2647/4885TAAR1 4585/4885DPP4 4223/4885 |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2C, ADRA2A | PNMT 73/4885TAAR1 27/4885DPP4 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.